NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Akero Therapeutics (AKRO) to $75 from $72 and keeps a Buy rating on the ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Y Intercept Hong Kong Ltd lessened its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 47.1% in the fourth ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Shares of AKRO stock opened at $45.54 on Monday. The stock’s 50-day moving average is $39.27 and its 200 day moving average is $32.78. Akero Therapeutics has a 1-year low of $17.86 and a 1-year ...

Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio? Check out this week's top-performing mid-cap stocks ...

In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing pharma stocks so far in 2025. On February 20, Jared Holz ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...